Novartis Entresto heart failure benefit but narrowly misses primary endpoint

• Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059)[1]
• Totality of evidence, including improvement in various measures of symptoms, quality of life, and renal function, suggests clinically important benefits in HFpEF[1]
• Entresto was well tolerated and the overall safety profile was comparable to previous findings in HFrEF patients

https://www.marketscreener.com/news/Novartis-PARAGON-HF-trial-suggests-Entresto-benefit-in-HFpEF-patients-but-narrowly-misses-primary-e–29144468/